5 May 2021 - CADTH has recommended that Ruzurgi (amifampridine) be reimbursed for the treatment of Lambert-Eaton myasthenic syndrome in individuals 6 and older, but only if certain conditions are met.
These include patients for whom the medication has been prescribed by a neurologist with experience caring for Lambert-Eaton myasthenic syndrome patients, and if Ruzurgi’s cost is reduced to a level that would be more acceptable to public payers.